New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
UroGen Pharma Ltd.
URGN
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

514M

Biotechnology

Next Earning date - 12 Nov 2024

514M

Biotechnology

Next Earning date - 12 Nov 2024

12.21USD
Shape0.11 ( 0.91%)
Market Open
favorite-chart

Relative Strenght

38
favorite-chart

Volume Buzz

-52%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

41%

Quote Panel

Shape
Updated October 25, 2024
1W -2.64 % 1M -4.39 % 3M -25.44 % 1Y 9.03 %

Key Metrics

Shape
  • Market Cap

    514.21M


  • Shares Outstanding

    42.11M


  • Share in Float

    38.20M


  • Dividende

    0


  • Earning Date

    12 Nov 2024


  • Price Target

    12.21


  • Average Volume

    574775


  • Beta

    1.119


  • Range

    10.6-20.7


  • Industry

    Biotechnology


  • Website

    https://www.urogen.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

6.05x

P/S Ratio

14.83x

P/B Ratio

3.3

Debt/Equity

-133.6%

Net Margin

$-3.1

EPS

How URGN compares to sector?

P/E Ratio

Relative Strength

Shape

URGN

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$141M

Shape547%

2025-Revenue

$2.65

Shape-192%

2025-EPS

$135M

Shape-427%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

EF Hutton

initialise

Previous: Not converted

2024-10-14

Now: Buy

Guggenheim

initialise

Previous: Not converted

2024-08-22

Now: Buy

Keefe, Bruyette & Woods

upgrade

Previous: Not converted

2024-06-14

Now: Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-1.13
vs -1.35

Q4.22

arrow
arrow

N/A

-1.22
vs -1.27

Q1.23

arrow
arrow

N/A

-1.30
vs -1.25

Q2.23

arrow
arrow

N/A

-1.03
vs -1.18

Q3.23

arrow
arrow

N/A

-0.68
vs -1.13

Q4.23

arrow
arrow

N/A

-0.72
vs -1.22

Q1.24

arrow
arrow

N/A

-0.97
vs -1.30

Q2.24

arrow
arrow

N/A

-0.91
vs -1.03

Q3.24

arrow
arrow

N/A

-0.82
vs -0.68

Q4.24

arrow
arrow

N/A

-0.77
vs -0.72

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+42%

16.1M  vs 11.4M

Q4.22

arrow
arrow

+12%

18.1M  vs 16.2M

Q1.23

arrow
arrow

+27%

17.2M  vs 13.6M

Q2.23

arrow
arrow

+27%

21.1M  vs 16.6M

Q3.23

arrow
arrow

+30%

20.9M  vs 16.1M

Q4.23

arrow
arrow

+30%

23.5M  vs 18.1M

Q1.24

arrow
arrow

+9%

18.8M  vs 17.2M

Q2.24

arrow
arrow

+3%

21.8M  vs 21.1M

Q3.24

arrow
arrow

+16%

24.2M  vs 20.9M

Q4.24

arrow
arrow

+20%

28.2M  vs 23.5M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

+41%

0.41
vs 0.65

Q4.22

arrow
arrow

+32%

0.32
vs 0.41

Q1.23

arrow
arrow

+26%

0.26
vs 0.32

Q2.23

arrow
arrow

+17%

0.17
vs 0.26

Q3.23

arrow
arrow

+52%

0.52
vs 0.17

Q4.23

arrow
arrow

+40%

0.4
vs 0.52

Q1.24

arrow
arrow

+80%

0.8
vs 0.4

Q2.24

arrow
arrow

-110%

-1.10
vs 0.8

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

61

61
vs 63

-3%

Q4.22

arrow
arrow

66

66
vs 61

8%

Q1.23

arrow
arrow

68

68
vs 66

3%

Q2.23

arrow
arrow

89

89
vs 68

31%

Q3.23

arrow
arrow

106

106
vs 89

19%

Q4.23

arrow
arrow

108

108
vs 106

2%

Q1.24

arrow
arrow

117

117
vs 108

8%

Q2.24

arrow
arrow

120

120
vs 117

3%

Earnings Growth

Latest News